Compare NAZ & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAZ | PLX |
|---|---|---|
| Founded | 1992 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.0M | 142.3M |
| IPO Year | N/A | 1998 |
| Metric | NAZ | PLX |
|---|---|---|
| Price | $11.96 | $2.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 18.3K | ★ 836.6K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $61,840,000.00 |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | N/A | $16.65 |
| P/E Ratio | ★ N/A | $29.53 |
| Revenue Growth | N/A | ★ 35.41 |
| 52 Week Low | $9.22 | $1.32 |
| 52 Week High | $11.37 | $3.10 |
| Indicator | NAZ | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 50.28 | 62.24 |
| Support Level | $11.93 | $1.97 |
| Resistance Level | $12.10 | $2.11 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 45.65 | 80.72 |
Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.